| NGRDX | VIGRX | NGRDX / VIGRX | |
| Total Expense Ratio | 0.55 | 0.17 | 324% |
| Annual Report Gross Expense Ratio | 0.56 | 0.17 | 329% |
| Fund Existence | 7 years | 34 years | - |
| Gain YTD | 7.299 | 7.252 | 101% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.59B | 385B | 1% |
| Annual Yield % from dividends | 0.00 | 0.26 | - |
| Returns for 1 year | -3.37 | 11.39 | -30% |
| Returns for 3 years | 33.88 | 83.29 | 41% |
| Returns for 5 years | 11.29 | 71.95 | 16% |
| Returns for 10 years | N/A | 378.71 | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MSSM | 58.61 | 0.43 | +0.73% |
| Morgan Stanley Pathway Sm-Md Cp Eq ETF | |||
| DRUP | 67.79 | 0.36 | +0.54% |
| GraniteShares Nasdaq Sel Disruptors ETF | |||
| IOPP | 26.51 | N/A | N/A |
| Simplify Tara India Opportunities ETF | |||
| HYXF | 45.93 | -0.08 | -0.17% |
| iShares ESG Advanced Hi Yld Corp Bd ETF | |||
| XBI | 156.20 | -0.62 | -0.40% |
| State Street® SPDR® S&P® Biotech ETF | |||